BioSpace News Archive

VBL Therapeutics, reminds its shareholders to vote in favor of the previously announced proposed merger with Notable Labs at the annual and special meeting for shareholders of record as of September 5, 2023.

AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023, before the market opens.

Starton Therapeutics Inc. announced the dosing of the first patient in the STAR-LLD Phase 1b clinical trial, which will assess the safety, efficacy and pharmacokinetics of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) for the treatment of multiple myeloma (MM).

Halberd Corporation’s (OTC PINK:HALB) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results.

Femasys Inc. today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): “The Past, The Present, and The Pipeline”, being held in New Orleans.

Align Technology, Inc. today announced that it will report third quarter 2023 financial results on Wednesday, October 25, 2023, after the close of market.

Shineco, Inc. announced that it plans to increase its research and development of new high-tech applications of silk protein in the health and medical field in conjunction with its existing silkworm business segment.

ViroCell Biologics, a specialist contract development and manufacturing organisation in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President of Business Development and Makis Sigalas as Senior Business Development Director.

EVONETIX LTD, the Company developing semiconductor scale technology to improve access to gene synthesis, announced its first placement of a DNA synthesis development platform for evaluation at Imperial College London.

BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the “Business Combination Agreement”), effective as of October 4, 2023.